Suppr超能文献

降低癌症粒细胞缺乏患者的发热和链球菌菌血症。口服青霉素V或安慰剂联合培氟沙星的试验。欧洲癌症研究与治疗组织国际抗菌治疗合作组

Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.

出版信息

JAMA. 1994 Oct 19;272(15):1183-9.

PMID:7933348
Abstract

OBJECTIVE

To determine the effect of oral penicillin V combined with a fluoroquinolone (pefloxacin) on the occurrence of fever and streptococcal and other gram-positive coccal bacteremic infections in granulocytopenic patients with cancer.

DESIGN

Prospective randomized double-blinded placebo-controlled prophylactic trial.

SETTING

Inpatient setting in multiple cooperating cancer centers.

SUBJECTS

Convenience sample with a total of 551 granulocytopenic patients, 95% of whom had leukemia or underwent bone marrow transplantation.

INTERVENTIONS

Penicillin V (500 mg twice a day) vs placebo given in combination with oral pefloxacin (400 mg twice a day).

MAIN OUTCOME MEASURES

Occurrence of fever and/or infection.

RESULTS

Fever or infection (without fever) developed in 190 (71%) of 268 evaluable patients in the penicillin arm compared with 213 (80%) of 268 evaluable patients in the placebo arm (P = .03; 95% confidence interval [CI] for the difference, -16% to -1%). Bacteremia occurred in 58 (22%) of 268 placebo-treated patients and in 38 (14%) of 268 penicillin-treated patients (P = .03; 95% CI for the difference, -14% to -1%), primarily due to a reduction in streptococcal bacteremic episodes that occurred in 14 penicillin-treated patients (5%) and in 27 placebo-treated patients (10%) (P = .05; 95% CI for the difference, -9% to -0.3%). Gram-negative rod bacteremias occurred in only two patients (1%) and in five patients (2%), respectively. Logistic regression analysis also supported the treatment effect on the development of bacteremia.

CONCLUSIONS

These results demonstrate that the addition of penicillin V to fluoroquinolone prophylaxis in granulocytopenic patients with cancer effectively reduces febrile episodes and the incidence of bacteremia, especially that due to streptococcal species.

摘要

目的

确定口服青霉素V联合氟喹诺酮类药物(培氟沙星)对癌症粒细胞缺乏患者发热及链球菌和其他革兰氏阳性球菌菌血症感染发生率的影响。

设计

前瞻性随机双盲安慰剂对照预防性试验。

地点

多个合作癌症中心的住院环境。

研究对象

便利样本,共551例粒细胞缺乏患者,其中95%患有白血病或接受了骨髓移植。

干预措施

青霉素V(每日两次,每次50�mg)与安慰剂联合口服培氟沙星(每日两次,每次400mg)。

主要观察指标

发热和/或感染的发生情况。

结果

青霉素组268例可评估患者中有190例(71%)出现发热或感染(无发热),而安慰剂组268例可评估患者中有213例(80%)出现发热或感染(P = 0.03;差异的95%置信区间[CI]为-16%至-1%)。268例接受安慰剂治疗的患者中有58例(22%)发生菌血症,268例接受青霉素治疗的患者中有38例(14%)发生菌血症(P = 0.03;差异的95%CI为-14%至-1%),主要原因是接受青霉素治疗的14例患者(5%)和接受安慰剂治疗的27例患者(10%)中链球菌菌血症发作减少(P = 0.05;差异的95%CI为-9%至-0.3%)。革兰氏阴性杆菌菌血症分别仅在2例患者(1%)和5例患者(2%)中发生。逻辑回归分析也支持了治疗对菌血症发生的效果。

结论

这些结果表明,在癌症粒细胞缺乏患者的氟喹诺酮类预防治疗中添加青霉素V可有效减少发热发作和菌血症的发生率,尤其是由链球菌引起的菌血症。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验